CRAIG FURMAN, Ph.D.
Head of Biology
Craig is an innovative cancer cell biologist with over fifteen years of drug discovery experience, including service at Pfizer and H3 biomedicine. Prior to joining dx/tx, Craig was an Associate Director at H3 Biomedicine, where he led project teams using both small molecule inhibitor and degrader approaches and directly contributed to the development of the covalent ER inhibitor H3B-6545. He is particularly interested in establishing cellular disease models and applying novel technologies to drive discovery and clinical translation efforts. Craig is skilled at initiating and managing relationships with industrial and academic partners, as well as selecting and developing talent to build high-performance teams.